Anti‐spike antibody durability after SARS‐CoV ‐2 vaccination in adolescent solid organ transplant recipients
Pediatric Transplantation · 2024
DOI: 10.1111/petr.14671 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Pediatric Transplantation, 2024. Verfasst von John McAteer und 17 weiteren Autor:innen. Beteiligte Einrichtung: Division of Infectious Diseases, Department of Pediatrics, Johns Hopkins Children's Center, Johns Hopkins University School of Medicine, Baltimore, M…. Hauptthemen laut MEDLINE: COVID-19, Organ Transplantation, Spike Glycoprotein, Coronavirus. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 9 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIDDK NIH HHS, NIAID NIH HHS, AHRQ HHS.
Abstract (Originalsprache)
Background
Adolescent solid organ transplant recipients (aSOTRs) who received three doses of the COVID‐19 mRNA vaccine experience high seroconversion rates and antibody persistence for up to 3 months. Long‐term antibody durability beyond this timeframe following three doses of the SARS‐CoV‐2 mRNA vaccine remains unknown. We describe antibody responses 6 months following the third vaccine dose (D3) of the BNT162b2 mRNA vaccination among aSOTRs.
Methods
Participants in a multi‐center, observational cohort who received the third dose of the vaccine were analyzed for antibodies to the SARS‐CoV‐2 spike protein receptor‐binding domain (Roche Elecsys anti‐SARS‐CoV‐2‐S positive: ≥0.8, maximum: >2500 U/mL). Samples were collected at 1‐, 3‐, and 6‐months post‐D3. Participants were surveyed at each timepoint and at 12‐months post‐D3.
Results
All 34 participants had positive anti‐RBD antibody titers 6 months post‐D3. Variations in titers occurred between 3 and 6 months post‐D3, with 8/28 (29%) having decreased antibody levels at 6 months compared to 3 months and 2/28 (7%) reporting increased titers at 6 months. The remaining 18/28 (64%) had unchanged antibody titers compared to 3‐month post‐D3 levels. A total of 4/34 (12%) reported breakthrough infection within 6 months and 3/32 (9%) reported infection after 6–12 months following the third dose of the SARS‐CoV‐2 mRNA vaccine.
Conclusions
The results suggest that antibody durability persists up to 6 months following three doses of the SARS‐CoV‐2 mRNA in aSOTRs. Demography and transplant characteristics did not differ for those who experienced antibody weaning. Breakthrough infections did occur, reflecting immune‐evasive nature of novel variants such as Omicron.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Infectious Diseases, Department of Pediatrics, Johns Hopkins Children's Center, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
- Division of Nephrology, Department of Pediatrics, Johns Hopkins Children's Center, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
- Department of Surgery, The Johns Hopkins Hospital, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
- Division of Cardiology, Department of Pediatrics, Children's Hospital Colorado, University of Colorado Anschutz Medical Campus, Aurora, Colorado, USA.
- Division of Infectious Diseases, Department of Pediatrics, Cincinnati Children's Hospital Medical Center, University of Cincinnati, Cincinnati, Ohio, USA.
- Division of Gastroenterology, Hepatology and Nutrition, Department of Pediatrics, Lucile Packard Children's Hospital Stanford, Stanford University School of Medicine, Palo Alto, California, USA.
ORCID-Profile: John McAteer, Divya D Kalluri, Rivka R Abedon, Caroline X Qin, Scott R Auerbach, Olga Charnaya, Lara A Danziger-Isakov, Noelle H Ebel, Amy G Feldman, Evelyn K Hsu, Saeed Mohammad, Emily R Perito, Teresa P Y Chiang, Jacqueline M Garonzik-Wang, Dorry L Segev, William A Werbel, Douglas B Mogul
Förderung
- NIDDK NIH HHS
- NIAID NIH HHS
- AHRQ HHS
- NIH HHS
- National Institute of Allergy and Infectious Diseases
- Agency for Healthcare Research and Quality
Zitieren
APA
McAteer, J., Kalluri, D. D., Abedon, R. R., Qin, C. X., Auerbach, S. R., Charnaya, O., Danziger-Isakov, L. A., Ebel, N. H., Feldman, A. G., Hsu, E. K., Mohammad, S., Perito, E. R., Thomas, A. M., Chiang, T. P. Y., Garonzik-Wang, J. M., Segev, D. L., Werbel, W. A., & Mogul, D. B. (2024). Anti‐spike antibody durability after SARS‐CoV ‐2 vaccination in adolescent solid organ transplant recipients. Pediatric Transplantation. https://doi.org/10.1111/petr.14671
Vancouver
McAteer J, Kalluri DD, Abedon RR, Qin CX, Auerbach SR, Charnaya O, et al. Anti‐spike antibody durability after SARS‐CoV ‐2 vaccination in adolescent solid organ transplant recipients. Pediatric Transplantation. 2024. doi:10.1111/petr.14671
BibTeX
@article{McAteer2024,
author = {McAteer, John and Kalluri, Divya D and Abedon, Rivka R and Qin, Caroline X and Auerbach, Scott R and Charnaya, Olga and Danziger-Isakov, Lara A and Ebel, Noelle H and Feldman, Amy G and Hsu, Evelyn K and Mohammad, Saeed and Perito, Emily R and Thomas, Ashley M and Chiang, Teresa P Y and Garonzik-Wang, Jacqueline M and Segev, Dorry L and Werbel, William A and Mogul, Douglas B},
title = {Anti‐spike antibody durability after SARS‐CoV ‐2 vaccination in adolescent solid organ transplant recipients},
journal = {Pediatric Transplantation},
year = {2024},
doi = {10.1111/petr.14671}
}
EUVIMED